Published in J Chromatogr B Analyt Technol Biomed Life Sci on March 25, 2003
Rotavirus anti-VP6 secretory immunoglobulin A contributes to protection via intracellular neutralization but not via immune exclusion. J Virol (2006) 1.22
Recognition of gram-positive intestinal bacteria by hybridoma- and colostrum-derived secretory immunoglobulin A is mediated by carbohydrates. J Biol Chem (2011) 0.98
Dectin-1 is essential for reverse transcytosis of glycosylated SIgA-antigen complexes by intestinal M cells. PLoS Biol (2013) 0.95
Potentiation of polarized intestinal Caco-2 cell responsiveness to probiotics complexed with secretory IgA. J Biol Chem (2010) 0.93
Antigen binding to secretory immunoglobulin A results in decreased sensitivity to intestinal proteases and increased binding to cellular Fc receptors. J Biol Chem (2009) 0.86
Agglutinating secretory IgA preserves intestinal epithelial cell integrity during apical infection by Shigella flexneri. Infect Immun (2013) 0.84
Human plasma-derived polymeric IgA and IgM antibodies associate with secretory component to yield biologically active secretory-like antibodies. J Biol Chem (2012) 0.80
Reconstituted human polyclonal plasma-derived secretory-like IgM and IgA maintain the barrier function of epithelial cells infected with an enteropathogen. J Biol Chem (2014) 0.77
Secretory component: a new role in secretory IgA-mediated immune exclusion in vivo. Immunity (2002) 2.17
Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen. Infect Immun (2005) 1.83
A malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparum. PLoS Med (2005) 1.75
Levocetirizine better protects than desloratadine in a nasal provocation with allergen. J Allergy Clin Immunol (2004) 1.49
Predictive value of antineutrophil cytoplasmic antibodies in small-vessel vasculitis. J Rheumatol (2005) 1.44
Pyelonephritic Escherichia coli expressing P fimbriae decrease immune response of the mouse kidney. J Am Soc Nephrol (2005) 1.43
Novel functions of the polymeric Ig receptor: well beyond transport of immunoglobulins. Trends Immunol (2003) 1.43
Selective adherence of IgA to murine Peyer's patch M cells: evidence for a novel IgA receptor. J Immunol (2002) 1.39
Secretory IgA-mediated neutralization of Shigella flexneri prevents intestinal tissue destruction by down-regulating inflammatory circuits. J Immunol (2009) 1.31
Secretory IgA mediates bacterial translocation to dendritic cells in mouse Peyer's patches with restriction to mucosal compartment. J Immunol (2007) 1.26
Zwitterionic polysaccharides stimulate T cells with no preferential V beta usage and promote anergy, resulting in protection against experimental abscess formation. J Immunol (2004) 1.21
Transcutaneous immunization using colonization factor and heat-labile enterotoxin induces correlates of protective immunity for enterotoxigenic Escherichia coli. Infect Immun (2002) 1.20
Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine. Vaccine (2005) 1.19
Secretory IgA possesses intrinsic modulatory properties stimulating mucosal and systemic immune responses. J Immunol (2005) 1.14
Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon α-kinoid. Arthritis Rheum (2013) 1.13
Glycans on secretory component participate in innate protection against mucosal pathogens. J Biol Chem (2006) 1.12
Allergen-specific T-cell tolerance induction with allergen-derived long synthetic peptides: results of a phase I trial. J Allergy Clin Immunol (2003) 1.10
Premature replacement of mu with alpha immunoglobulin chains impairs lymphopoiesis and mucosal homing but promotes plasma cell maturation. Proc Natl Acad Sci U S A (2010) 1.09
Microaerophilic conditions permit to mimic in vitro events occurring during in vivo Helicobacter pylori infection and to identify Rho/Ras-associated proteins in cellular signaling. J Biol Chem (2002) 1.08
Inhibition of HIV-1 infectivity and epithelial cell transfer by human monoclonal IgG and IgA antibodies carrying the b12 V region. J Immunol (2007) 1.06
Particulate formulations for the delivery of poly(I:C) as vaccine adjuvant. Adv Drug Deliv Rev (2013) 1.02
Targeting of secretory IgA to Peyer's patch dendritic and T cells after transport by intestinal M cells. J Immunol (2004) 1.01
N-Glycans on secretory component: mediators of the interaction between secretory IgA and gram-positive commensals sustaining intestinal homeostasis. Gut Microbes (2011) 1.01
Secretory IgA induces tolerogenic dendritic cells through SIGNR1 dampening autoimmunity in mice. J Immunol (2013) 0.99
Recognition of gram-positive intestinal bacteria by hybridoma- and colostrum-derived secretory immunoglobulin A is mediated by carbohydrates. J Biol Chem (2011) 0.98
Solution structure of human secretory component and implications for biological function. J Biol Chem (2007) 0.98
Dectin-1 is essential for reverse transcytosis of glycosylated SIgA-antigen complexes by intestinal M cells. PLoS Biol (2013) 0.95
Induction of human papillomavirus oncogene-specific CD8 T-cell effector responses in the genital mucosa of vaccinated mice. Int J Cancer (2010) 0.94
Impact of the molecular form of immunoglobulin A on functional activity in defense against Streptococcus pneumoniae. Infect Immun (2007) 0.93
Potentiation of polarized intestinal Caco-2 cell responsiveness to probiotics complexed with secretory IgA. J Biol Chem (2010) 0.93
The role of secretory immunoglobulin A in the natural sensing of commensal bacteria by mouse Peyer's patch dendritic cells. J Biol Chem (2012) 0.92
Behçet's disease in Western Switzerland: epidemiology and analysis of ocular involvement. Ocul Immunol Inflamm (2002) 0.92
Transient suppression of Shigella flexneri type 3 secretion by a protective O-antigen-specific monoclonal IgA. MBio (2011) 0.91
Asthma control in Switzerland: a general practitioner based survey. Curr Med Res Opin (2006) 0.88
Randomized double-blind controlled Phase I/IIa trial to assess the efficacy of malaria vaccine PfCS102 to protect against challenge with P. falciparum. Vaccine (2010) 0.88
Food products and allergy development, prevention and treatment. Curr Opin Biotechnol (2006) 0.88
Antigen binding to secretory immunoglobulin A results in decreased sensitivity to intestinal proteases and increased binding to cellular Fc receptors. J Biol Chem (2009) 0.86
Individualising HIV treatment--pharmacogenetics and immunogenetics. Lancet (2002) 0.86
Agglutinating secretory IgA preserves intestinal epithelial cell integrity during apical infection by Shigella flexneri. Infect Immun (2013) 0.84
Allergic rhinitis in patients with asthma: the Swiss LARA (Link Allergic Rhinitis in Asthma) survey. Curr Med Res Opin (2009) 0.84
Passive immunity in Helicobacter-challenged neonatal mice conferred by immunized dams lasts until weaning. Infect Immun (2003) 0.83
Retracted Oxidized low-density lipoproteins activate CD4+ T cell apoptosis in patients with end-stage renal disease through Fas engagement. J Am Soc Nephrol (2006) 0.83
CD4+CD25-mTGFbeta+ T cells induced by nasal application of ovalbumin transfer tolerance in a therapeutic model of asthma. Int Immunol (2010) 0.82
Novel birch pollen specific immunotherapy formulation based on contiguous overlapping peptides. Clin Transl Allergy (2013) 0.81
Lactobacillus bulgaricus proteinase expressed in Lactococcus lactis is a powerful carrier for cell wall-associated and secreted bovine beta-lactoglobulin fusion proteins. Appl Environ Microbiol (2002) 0.81
Role of secretory IgA in the mucosal sensing of commensal bacteria. Gut Microbes (2014) 0.80
Human plasma-derived polymeric IgA and IgM antibodies associate with secretory component to yield biologically active secretory-like antibodies. J Biol Chem (2012) 0.80
Intragastric and Intranasal Administration of Lactobacillus paracasei NCC2461 Modulates Allergic Airway Inflammation in Mice. Int J Inflam (2012) 0.80
Prevention of cryoprecipitation during cardiopulmonary bypass in a patient with HIV-HCV co-infections. Perfusion (2006) 0.80
Malaria vaccine candidate: design of a multivalent subunit α-helical coiled coil poly-epitope. Vaccine (2011) 0.80
The synthetic Plasmodium falciparum circumsporozoite peptide PfCS102 as a malaria vaccine candidate: a randomized controlled phase I trial. PLoS One (2009) 0.79
Tuning the immune response of dendritic cells to surface-assembled poly(I:C) on microspheres through synergistic interactions between phagocytic and TLR3 signaling. Biomaterials (2011) 0.78
Plasmodium falciparum merozoite surface protein 2: epitope mapping and fine specificity of human antibody response against non-polymorphic domains. Malar J (2014) 0.78
Malaria vaccines - The long synthetic peptide approach: Technical and conceptual advancements. Curr Opin Mol Ther (2010) 0.78
Gas-filled microbubble-mediated delivery of antigen and the induction of immune responses. Biomaterials (2012) 0.77
Human polymeric IgA is superior to IgG and single-chain Fv of the same monoclonal specificity to inhibit urease activity associated with Helicobacter pylori. Mol Immunol (2004) 0.77
Secretory IgA as a vaccine carrier for delivery of HIV antigen to M cells. Eur J Immunol (2015) 0.76
Shrinking lung syndrome successfully treated with rituximab and cyclophosphamide. Respiration (2012) 0.76
Improved diagnoses of autoimmune hepatitis using an anti-actin ELISA. J Clin Lab Anal (2008) 0.76
The phagocytosis of gas-filled microbubbles by human and murine antigen-presenting cells. Biomaterials (2011) 0.76
Severe anaphylactic shock to Patent Blue V with cardiac arrest during breast carcinoma surgery with lymphatic mapping. Eur J Obstet Gynecol Reprod Biol (2007) 0.76
Rotavirus specific plasma secretory immunoglobulin in children with acute gastroenteritis and children vaccinated with an attenuated human rotavirus vaccine. Hum Vaccin Immunother (2013) 0.76
The effect of vaccines based on ovalbumin coupled to gas-filled microbubbles for reducing infection by ovalbumin-expressing Listeria monocytogenes. Biomaterials (2013) 0.76
Ex vivo monitoring of antigen-specific CD4+ T cells after recall immunization with tetanus toxoid. Clin Vaccine Immunol (2007) 0.75
Presence of Gal-alpha1,3Gal epitope on xenogeneic lines: implications for cellular gene therapy based on the encapsulation technology. Xenotransplantation (2003) 0.75
[Not Available]. Rev Med Suisse (2016) 0.75
[If you go looking for trouble you'll find it. Urticarial reactions to insects of our local areas]. Rev Med Suisse (2016) 0.75
Surface assembly of poly(I:C) on PEGylated microspheres to shield from adverse interactions with fibroblasts. J Control Release (2012) 0.75
[Use of autoantibodies in clinical practice]. Rev Med Suisse (2009) 0.75
[Allergic rhinoconjunctivitis and immunotherapy: an update]. Rev Med Suisse (2009) 0.75
Unsatisfactory outcomes in myasthenia gravis: influence by care providers. J Neurol (2009) 0.75
[Peripheral blood eosinophilia: diagnostic value and further assessment]. Rev Med Suisse (2013) 0.75
[Mastocytosis: when should it be considered?]. Rev Med Suisse (2009) 0.75
[Allergology and clinical immunology: a crossover discipline]. Rev Med Suisse (2009) 0.75
[Beyond borders]. Rev Med Suisse (2011) 0.75
Toward protein biomarkers for allergy: CD4+ T cell proteomics in allergic and nonallergic subjects sampled in and out of pollen season. J Proteome Res (2011) 0.75
[Large vessel vasculitis: giant cell arteritis and Takayasu arteritis]. Rev Med Suisse (2007) 0.75
Successful therapy with mycophenolic acid in a membranous glomerulonephritis due to Kimura disease . Clin Nephrol (2017) 0.75
[From a wide gap to reciprocal enrichment: a wager for the Swiss Society of Allergy and Immunology]. Rev Med Suisse (2006) 0.75
[Severe delayed drug hypersensitivity reactions]. Rev Med Suisse (2013) 0.75
[Therapeutic strategies in idiopatic inflammatory myopathies]. Rev Med Suisse (2009) 0.75
[Food allergy in children: a diagnostic challenge]. Rev Med Suisse (2016) 0.75
[About the article "Sports and immunology-allergology]. Rev Med Suisse (2005) 0.75
Modulation of allergic responses in mice by using biodegradable poly(lactide-co-glycolide) microspheres. J Allergy Clin Immunol (2004) 0.75